Celsion Corporation Announces the Appointment of Gary Renshaw, D.O., as Executive Medical Director

COLUMBIA, MD--(Marketwire - August 25, 2011) - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today the appointment of Gary Renshaw, D.O., as Executive Medical Director, effective August 29, 2011. Dr. Renshaw will report to Nicholas Borys, M.D., Celsion’s Chief Medical Officer.

“Gary possesses an extensive record of successful drug development in oncology, with clinical and regulatory experience at all stages of the development process,” said Michael H. Tardugno, Celsion’s President and Chief Executive Officer. “As we work toward the interim analysis and final data from our pivotal Phase III HEAT Study of ThermoDox® in primary liver cancer, we will look to rapidly expand the clinical study of this important drug candidate into other cancers, including metastatic liver, bone and recurrent chest wall breast cancers, where it has been shown to enhance the efficacy of existing heat-based treatments. We look forward to Dr. Renshaw’s contributions to this effort as we continue evolving Celsion as a leading developer of innovative oncology therapeutics.”

Dr. Renshaw brings to Celsion over 20 years of academic and industry drug development experience. Most recently, he served as a consultant to DelCath Systems. Prior to this, Dr. Renshaw was Global Executive Director, Oncology/Hematology R&D, at Celgene Corporation from 2008 to 2011; Director, Hematology/Oncology division, at Johnson & Johnson PRD from 2005 to 2008; Medical Oncology Director at EISAI Co. from 2003 to 2005; and Clinical Research Physician, U.S. Medical Affairs, at Eli Lily and Company from 2001 to 2003. Dr. Renshaw has held faculty positions at Michigan State University and the University of Missouri, and has served on the Immuno-Molecular Therapeutics and Melanoma Committees for the Southwest Oncology Group, the American Osteopathic Association Boards Committee, the Editorial Board of “The American Journal of Hospice & Palliative Care” and the NCI PAN-CAN Board. He holds a D.O. degree from the University of Medicine and Dentistry of New Jersey, a B.S. degree in biomedical chemistry from Oral Roberts University, and conducted graduate studies in biochemistry at the University of Pennsylvania. Dr. Renshaw resides in New Jersey, where Celsion plans to relocate its operations and corporate headquarters in the fourth quarter of this year.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.